Internal Medicine, Hematology & Oncology · Chula Vista, CA
NPI
1063527711
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
769 Medical Center Ct, Suite 202
Chula Vista, CA, 91911
Phone (619) 482-8430
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
270,264 services
Medicare patients, 2024
572
Average age 75
Drug cost, 2024
$7.4M
1,420 prescriptions
Company payments, 2025
$1,772
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth B Johnson was code J1439 (injection, ferric carboxymaltose, 1 mg), 105,750 times for 58 patients. In total Kenneth B Johnson billed 270,264 services in 79 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-07-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 105,750 | 58 | $0.87 | $92K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 80,700 | 52 | $2.32 | $187K |
| J0897 Injection, denosumab, 1 mg | Office | 7,500 | 26 | $20.45 | $153K |
| 85025 Blood Count | Office | 1,633 | 482 | $7.61 | $12K |
| 36415 Venipuncture Blood Collection | Office | 1,593 | 489 | $8.65 | $14K |
| 99214 Office E&M - Established | Office | 977 | 441 | $86.82 | $85K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 740 | 13 | $0.25 | $186 |
| 96372 Injection Administration | Office | 490 | 94 | $10.64 | $5,213 |
| 96413 Chemotherapy Administration | Office | 181 | 26 | $102.57 | $19K |
| 99213 Office E&M - Established | Office | 124 | 100 | $63.40 | $7,862 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 111 | 17 | $0.94 | $104 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 108 | 12 | $128.89 | $14K |
| 96374 Injection Administration | Office | 104 | 46 | $29.16 | $3,033 |
| 96415 Chemotherapy Administration | Office | 98 | 12 | $22.39 | $2,194 |
| 96375 Injection Administration | Office | 95 | 15 | $12.44 | $1,182 |
By year: 2022 $1.6M for 216,007 services; 2023 $1.8M for 249,255 services; 2024 $1.8M for 270,264 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,633 | 482 | $7.61 | $12K |
| 36415 Venipuncture Blood Collection | 1,593 | 489 | $8.65 | $14K |
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth B Johnson prescribed most often to Medicare patients was Anastrozole, with 116 prescriptions and refills. In total Kenneth B Johnson wrote 1,420 Medicare prescriptions that cost $7.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 116 | 313 | 32 | $1,707 |
| Oxycodone Hcl Generic | 76 | 77 | 13 | $3,166 |
| Xtandi Enzalutamide | 58 | 58 | Under 11 | $774K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 56 | 56 | Under 11 | $2,802 |
| Ondansetron Hcl Generic | 54 | 54 | 19 | $499 |
| Revlimid Lenalidomide | 47 | 47 | Under 11 | $1.0M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 40 | 40 | Under 11 | $1,540 |
| Lenalidomide Generic | 38 | 38 | Under 11 | $603K |
| Morphine Sulfate Er Morphine Sulfate | 37 | 37 | Under 11 | $2,298 |
| Hydroxyurea Generic | 35 | 96 | 13 | $1,466 |
| Letrozole Generic | 33 | 75 | Under 11 | $931 |
| Fentanyl Generic | 31 | 31 | Under 11 | $2,566 |
| Eliquis Apixaban | 31 | 53 | Under 11 | $30K |
| Jakafi Ruxolitinib Phosphate | 28 | 28 | Under 11 | $484K |
| Imatinib Mesylate Generic | 27 | 33 | Under 11 | $50K |
Brand drugs: 506 claims; generic drugs: 914 claims; opioid claims: 300.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth B Johnson $1,772 ($1,772 in general payments such as food, travel and fees) from 33 companies. The largest payer was Pfizer Inc. with $169.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 8 | $169 |
| Merck Sharp & Dohme LLC MRK | 4 | $121 |
| Abbvie Inc. ABBV | 5 | $109 |
| Aveo Pharmaceuticals, Inc. | 1 | $99.95 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $95.42 |
| Gilead Sciences, Inc. GILD | 3 | $93.44 |
| Daiichi Sankyo Inc. 4568.T | 3 | $86.48 |
| Celgene Corporation BMY | 3 | $86.1 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $85.85 |
| Alexion Pharmaceuticals, Inc. AZN | 3 | $77.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.